Robin Swartz was named President of Voyager Therapeutics, Inc. As of November 6, 2026, Voyager Therapeutics, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 21, 2026 to October 21, 2026, naming 2 appointments (Form 8-K, October 21, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Voyager Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Voyager Therapeutics, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-21 to 2026-10-21. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Voyager Therapeutics, Inc. files it.
Also on the record for Voyager Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 5.58% of the class | 5%+ stakes | Source |
| July 31, 2026 | Stake report, Schedule 13G/A, by Millennium Management LLC | 7.4% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 5.87% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by EcoR1 Capital, LLC | — | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 18, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 7.19% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by EcoR1 Capital, LLC | 6.8% of the class | 5%+ stakes | Source |
| January 26, 2026 | Stake report, Schedule 13G, by Millennium Management LLC | 6.1% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 7.57% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by EcoR1 Capital, LLC | 6.8% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 8.65% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Voyager Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Voyager Therapeutics, Inc. and the records around it.
Voyager Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- EcoR1 Capital, LLC also filed stake reports on 20 other companies: Mereo BioPharma Group plc (Aug 2026), Alto Neuroscience, Inc. (Jul 2026), Fulcrum Therapeutics, Inc. (Jun 2026)
- Integrated Core Strategies (US) LLC also filed stake reports on 63 other companies: SkinHealth Systems Inc. (Nov 2026), Infinite Eagle Acquisition Corp. (Nov 2026), Longeveron Inc. (Nov 2026)
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Watch Voyager Therapeutics, Inc.
Get an email when Voyager Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Voyager Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Voyager Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Voyager Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-21 | In | President | 8-K, 2026-10-21 | ||
| 2026-04-21 | In | Director | 8-K, 2026-04-21 |
Who leads Voyager Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- President: Robin Swartz, appointed (filed 2026-10-21).
- Director: Robin Swartz, appointed (filed 2026-04-21).
New leaders reset buying decisions — get the Full Report on Voyager Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the President at Voyager Therapeutics, Inc., with the record behind each one.
Find candidates like President at Voyager Therapeutics, Inc.Every change, in the filing's words
Appointed: Robin Swartz, President
On October 20, 2026 (the "Effective Date"), the Board of Directors (the "Board") of Voyager Therapeutics, Inc. (the "Company") appointed Robin Swartz, the Company's Chief Business Officer and Chief Operating Officer, to serve as President of the Company, effective immediately.
- Ms. Swartz is also expected to succeed Alfred W. Sandrock, Jr., M.D., Ph.D. as Chief Executive Officer of the Company following the anticipated receipt in the first quarter of 2027 of initial acute safety data in connection with its clinical trial of VY1706 in adults with early Alzheimer's Disease.
- Dr. Sandrock is expected to continue to serve as a member of the Board following Ms. Swartz's anticipated succession.
- Ms. Swartz, age 56, has served as the Company's Chief Operating Officer and Chief Business Officer since November 2024 and as the Company's Principal Financial Officer and Treasurer since May 2026.
- She previously served as the Company's Chief Operating Officer from February 2022 to November 2024, the Company's Principal Financial Officer and Principal Accounting Officer from April 2024 to July 2024, the Company's Senior Vice President, Business Operations from September 2021 to February 2022 and the Company's Senior Vice President, Portfolio Management and Patient Engagement from January 2021 to August 2021.
Appointed: Robin Swartz, Director
Election of Robin Swartz In connection with the transition of Dr. Jorgensen, on April 20, 2026, the board of directors of the Company appointed Robin Swartz to assume the roles of principal financial officer and treasurer of the Company, effective as of the Effective Time.
- Resignation of Chief Financial Officer On April 15, 2026, Nathan Jorgensen, Ph.D. notified Voyager Therapeutics, Inc. (the "Company") of his decision to resign from his position as Chief Financial Officer of the Company and from any and all other positions he holds with the Company and any of its subsidiaries, effective May 8, 2026 (the effective time of Dr. Jorgensen's transition, the "Effective Time"), to pursue a new opportunity.
- Dr. Jorgensen's resignation is not a result of any disagreement with the Company.
- Ms. Swartz, age 55, has served as the Company's Chief Operating Officer and Chief Business Officer since November 2024, and previously served as the Company's Chief Operating Officer from February 2022 to November 2024, the Company's Principal Financial Officer and Principal Accounting Officer from April 2024 to July 2024, the Company's Senior Vice President, Business Operations from September 2021 to February 2022 and the Company's Senior Vice President, Portfolio Management and Patient Engagement from January 2021 to August 2021.
Tools for this story
Each opens in a new tab, filled in for Voyager Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.